Sato Hiroyuki, Nagasawa Tasuku, Saito Ayako, Miyazaki Mariko
Department of Nephrology, Hypertension and Endocrinology, Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan.
Department of Nephrology, Japanese Red Cross Ishinomaki Hospital, 71 Nisimitishita Hebita, Ishinomaki, Miyagi, 986-8522, Japan.
Clin Exp Nephrol. 2018 Aug;22(4):957-966. doi: 10.1007/s10157-017-1527-1. Epub 2018 Jan 4.
The relationship between serum corrected calcium (CCa) level and vessel calcification at dialysis initiation and survival has seldom been evaluated. Therefore, we evaluated the efficacy of CCa levels and the calcification score at the initiation of dialysis for predicting all-cause and cardiovascular (CV) mortality in patients with end-stage renal disease (ESRD).
The study group included 407 patients with ESRD, who started hemodialysis between January 2009 and December 2016 at the Red Cross Ishinomaki Hospital. The primary outcomes were the 1- and 3-year all-cause and CV mortality rate, with the association between CCa level and CVD-specific mortality evaluated using the Kaplan-Meier method and Cox proportional hazard regression analysis.
Patients with a high initial CCa level were at higher risk for CVD-related, but not all-cause, mortality than patients with a low initial CCa level [hazard ratio (HR) 2.81; 95% confidence interval 1.05-7.55]. The HR for CVD-related mortality was also higher for patients with an Agatston vessel calcification score > 2000 (HR 13.9; 95% CI 1.63-118.2). Overall, the 3-year CVD-free rate was 88.2% (range 76.4-94.3%). Higher CCa level was associated with a higher Agatston score and cardiac valve calcification.
High serum CCa levels and an Agatston score > 2000 are independent risk factors of CVD mortality due to advanced vessel calcification.
很少有研究评估透析起始时血清校正钙(CCa)水平与血管钙化及生存之间的关系。因此,我们评估了透析起始时CCa水平和钙化评分对预测终末期肾病(ESRD)患者全因死亡和心血管(CV)死亡的效果。
研究组包括407例ESRD患者,他们于2009年1月至2016年12月期间在石卷红十字医院开始进行血液透析。主要结局为1年和3年的全因死亡率和CV死亡率,使用Kaplan-Meier法和Cox比例风险回归分析评估CCa水平与CVD特异性死亡率之间的关联。
初始CCa水平高的患者相比初始CCa水平低的患者,发生CVD相关死亡(而非全因死亡)的风险更高[风险比(HR)2.81;95%置信区间1.05 - 7.55]。阿加西顿血管钙化评分>2000的患者CVD相关死亡的HR也更高(HR 13.9;95% CI 1.63 - 118.2)。总体而言,3年无CVD发生率为88.2%(范围76.4 - 94.3%)。较高的CCa水平与较高的阿加西顿评分和心脏瓣膜钙化相关。
高血清CCa水平和阿加西顿评分>2000是晚期血管钙化导致CVD死亡的独立危险因素。